scPharmaceuticals Inc
SCPH
View Detailed Chart
5.620USD
-0.010-0.18%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
299.49MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.18%
5 Days
-0.18%
1 Month
+17.57%
6 Months
+84.26%
Year to Date
+58.76%
1 Year
+3.50%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Hold
Current Rating
12.088
Target Price
+115.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Growing
The company is in a growing phase, with the latest annual income totaling USD 36.33M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 131.14.
Fairly Valued
The company’s latest PE is -3.10, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.86M shares, decreasing 18.37% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.84M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.31.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Ticker SymbolSCPH
CompanyscPharmaceuticals Inc
CEOMr. John H. Tucker
Websitehttps://www.scpharmaceuticals.com/
Related Instruments
+0.37%
-1.72%
+0.53%
-0.80%
-0.15%
+6.27%
+0.48%
+0.41%
+1.21%
+0.42%
+1.51%
-0.01%
-1.19%
-0.30%
-0.15%
-1.70%
-0.03%
+0.12%
+2.26%
+0.10%
